HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
Norgine is committed to making information about its clinical research publicly available, irrespective of the outcomes, positive or negative, in order to support the scientific understanding of its medicines and medical devices and their benefits and risks to patients.
Norgine discloses clinical trial results of all new medicines and medical devices in accordance with the regulations to ensure rigorous assessment of their quality, safety and efficacy before they are approved and made available to patients. Regulatory review is maintained throughout the life cycle of our medicines and medical devices and the benefits and risks associated with these medicines and medical devices are continuously reviewed by Norgine in collaboration with regulatory authorities.
The results of our clinical trials in all stages of clinical development are disclosed in several ways: